On Monday, the Third Circuit denied a motion to reconsider its prior ruling in the case of AbbVie – a high-profile pharmaceutical company. The previous ruling had determined that AbbVie was unable to provide sufficient evidence demonstrating that the lower court had contradicted existing precedent, or made substantial errors when it ordered the drugmaker to reveal attorney communications pertaining to an alleged patent case. Said case was seemingly intended to stall a competitor of AndroGel, AbbVie’s flagship product.
The order from the lower court compelling AbbVie to disclose these attorney communications is a subject of considerable contention, given the company’s claim that this decision breached established norms. However, after careful review, the Third Circuit found no grounds to reverse or make alterations to the verdict.
An in-depth analysis of the legal complexities and substantial ramifications of this decision can be found in the original Law360 article.